Abstracts tagged "spondyloarthritis"

Abstract Number: 1395 • ACR Convergence 2023
Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Elisabet Lindqvist¹, Johan Karlsson Wallman¹, Jonas Sagard², Tor Olofsson¹ and Elisabeth Mogard¹, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Skåne University Hospital, Lund, Sweden
Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…
Abstract Number: 1781 • ACR Convergence 2023
TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis
Yehao Li and Xiang Peng, Department of Rheumatology and Immunology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, China
Background/Purpose: Emerging studies have shown that neutrophil extracellular traps (NETs) are increased and associated with the disease activity in patients with axial spondyloarthritis (axSpA). However,…
Abstract Number: 2077 • ACR Convergence 2023
A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Elaine Bell¹, Marinella Calle² and Iain McInnes³, ¹Medscape Global Education, London, United Kingdom, ²MEDSCAPE GLOBAL, London, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…
Abstract Number: 2210 • ACR Convergence 2023
Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis
Pieter Ruytinx¹, Elien Luyten¹, Ann-Sophie De Craemer², Filip Van den Bosch³, Dirk Elewaut⁴ and Veerle Somers¹, ¹Biomedical Research Institute, Hasselt University, Department of Immunology and Infection, Diepenbeek, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, an axSpA cDNA phage display library, constructed from…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 0489 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients with psoriatic arthritis (PsA) in previous randomized clinical trials [1]. There is only limited…
Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni¹, Philip J. Mease², Joseph Merola³, Frank Behrens⁴, Ennio G Favalli⁵, Dennis McGonagle⁶, William R Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Jason Coarse¹¹ and Laure Gossec¹², ¹Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁵ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁶Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁷Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Irigny, France, ¹¹UCB Pharma, Morrisville, NC, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…
Abstract Number: 0845 • ACR Convergence 2023
The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: We have shown in the SPACE cohort that a diagnosis of early axial Spondyloarthritis (axSpA) can be reliably made in patients with chronic back…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Catherine Manning¹, Nataliya Yeremenko², Jae-Hyuck Shim³, Daniel Montoro⁴, Dominique Baeten⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵UCB Pharma, Slough, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Miranda Van Lunteren², Mary Lucy marques³, Karen Fagerli⁴, Sofia Ramiro⁵, Désirée van der Heijde⁵ and Floris Van Gaalen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ³Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…
Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
William R Tillett¹, Joseph Merola², Yoshiya Tanaka³, Ennio G Favalli⁴, Dennis McGonagle⁵, Diamant Thaçi⁶, Jessica A Walsh⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and Christopher T Ritchlin¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰University of Rochester Medical School, Rochester, NY
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…
Abstract Number: 0492 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
rodrigo garcía salinas¹, Gisel Reyes², Rosario Jaldín Céspedes², Felica Almada² and Sebastián Juan Magri³, ¹Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…
Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].